(Total Views: 727)
Posted On: 07/01/2020 11:58:42 PM
Post# of 153892
Re: reallypeople? #40551
“If the severe critical trial showed overwhelming evidence of less deaths already why wasn’t the trial stopped for efficacy.”
Simple answer: CYDY hasn’t seen the unblinded data, thus, they don’t know if there are more deaths in the placebo arm vs leronlimab arm. That’s a fact. What many are discussing here is the FDA returning to CYDY and saying, “Hey, 51 patients isn’t enough for an interim analysis, get to 150 patients and then conduct one.”
We won’t know when the interim analysis on the severe trial will happen until we get more news from NP. Until then, we should be happy the trial is enrolling as quickly as it had been.
Simple answer: CYDY hasn’t seen the unblinded data, thus, they don’t know if there are more deaths in the placebo arm vs leronlimab arm. That’s a fact. What many are discussing here is the FDA returning to CYDY and saying, “Hey, 51 patients isn’t enough for an interim analysis, get to 150 patients and then conduct one.”
We won’t know when the interim analysis on the severe trial will happen until we get more news from NP. Until then, we should be happy the trial is enrolling as quickly as it had been.
(3)
(0)
